Press Room


    Press Release - August 31, 2009

    Notice of Allowance Issued for Key Patent for Sernova's Sertoli Cell Platform

    London, Ontario -- August 31, 2009 - Sernova Corp. (TSX-V: SVA) today announced that the Canadian Patent Office has issued a Notice of Allowance for a key patent related to its genetically modified sertoli cell platform. International patents are still pending.

    The Patent, entitled "Production of a Biological Factor and Creation of an Immunologically Privileged Environment Using Genetically Altered Sertoli Cells", claims the use of Sertoli cells that have been genetically modified to produce biological factors important in the prevention and treatment of a wide range of diseases. The Notice of Allowance was issued July 13th, 2009 to Sertoli Technologies, Inc., the exclusive licensor to Sernova Corp.

    "This patent adds to our extensive portfolio of over 20 issued and pending patents" said Dr. Philip Toleikis, Sernova's President and CEO. "The broad claims in this patent position Sernova with the potential to extend its Sertoli cell platform beyond our current focus of insulin- dependent diabetes to the treatment of a wide range of disorders including Parkinson's disease, blood disorders (haemophilia, hyperbilirubinemia, hemoglobinopathies such as sickle-cell disease, anaemia in chronic kidney disease, and related to cancer chemotherapy); the prevention of infection in susceptible individuals such as oncology patients, AIDS patients and those with other white blood cell diseases, as well as the prevention or treatment of certain cancers in genetically predisposed populations."

    Naturally occurring Sertoli cells possess a unique ability to maintain an immune-privileged environment. In combination with Sernova's novel Cell Pouch System(tm), Sertoli cells may potentially be used in a variety of settings to eliminate the need for expensive and toxic immunosuppressive drugs. Sernova's genetically modified Sertoli cell platform combined with Sernova's novel Cell Pouch System(tm) further enables the potential replacement of key natural substances in the body, or to produce therapeutic agents to prevent or treat disease.

    Sernova anticipates that the expansion of its current programs will occur through a combination of internal research efforts, as well as external corporate and academic collaborations.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(tm) and its patented Sertolin(tm) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News